FDA approves new Gilead HIV therapy, reinforcing lenacapavir franchise
Gilead Sciences secured a new FDA approval for an HIV treatment on Thursday, strengthening its already dominant position in the market. The approval builds on the success of lenacapavir, the company's key HIV drug. The new therapy adds to Gilead's arsenal against the virus.
Related stories
Roivant wins FDA approval for first oral dermatomyositis treatment · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Gilead gets another HIV treatment approval, extending lenacapavir's dominance.” Browse more stories.